Klangjorhor Jeerawan, Pongnikorn Donsuk, Phanphaisarn Areerak, Chaiyawat Parunya, Teeyakasem Pimpisa, Suksakit Pathacha, Pasena Arnat, Udomruk Sasimol, Orrapin Santhasiri, Pornwattanavate Samatit, Waisri Narate, Daoprasert Karnchana, Wisanuyotin Taweechok, Santong Chalongpon, Sangrajrang Suleeporn, Sitthikong Siriphon, Tuntarattanapong Pakjai, Prechawittayakul Paradee, Pruksakorn Dumnoensun
Musculoskeletal Science and Translational Research Center, Department of Orthopedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand.
Cancer Registry Unit, Lampang Cancer Hospital, Lampang, Thailand.
Cancer Epidemiol. 2022 Feb;76:102056. doi: 10.1016/j.canep.2021.102056. Epub 2021 Nov 16.
Epidemiology data from population-based cancer registries (PBCR) can be very valuable in the development of health policy and for improving the quality of cancer control strategies.
This study analyzed the incidence of bone sarcomas in Thailand during 2001 - 2015 by analyzing data obtained from 5 PBCRs across country. Incidence rates per million person-years by sex, histological subtype, primary site and 5-year age group were calculated. Age-standardized incidence rates (ASR) were adjusted using the WHO's World Standard Population and comparisons between populations were done using standardized rate ratios (SRR). Incidence trends were evaluated using Joinpoint Trend Analysis. Survival rates were analyzed using STATA.
The ASR of bone sarcomas in Thailand was 5.1/10 person-years, with an estimated 328 newly diagnosed bone sarcomas per year for the country overall. Osteosarcoma (52.5%), chondrosarcoma (18%), Ewing's sarcoma (11.6%), giant cell tumor (4.8%) and chordoma (4.7%) were the most common malignant bone tumors, representing 91.5% of all bone sarcomas. Bone sarcoma has a predilection for males (1.29:1) and an age-specific bimodal rate pattern closely related to the major histological subtypes, osteosarcoma. One- and five-year survival rates of Thai patients with bone sarcoma were 74% and 52%, respectively. Survival rates of bone sarcomas, particularly osteosarcoma, were lower than the rates reported from the United States, Europe and Japan.
The lower overall survival rate of bone sarcoma represented the gap of bone sarcoma control program in Thailand. That indicates the need for improvement in health promotion, treatment process and chemotherapy for bone sarcoma patients in the future.
基于人群的癌症登记处（PBCR）的流行病学数据在卫生政策制定和改善癌症控制策略质量方面可能非常有价值。
本研究通过分析从全国5个PBCR获得的数据，分析了2001 - 2015年泰国骨肉瘤的发病率。计算了按性别、组织学亚型、原发部位和5岁年龄组划分的每百万人口年发病率。使用世界卫生组织的世界标准人口对年龄标准化发病率（ASR）进行调整，并使用标准化率比（SRR）对人群之间进行比较。使用Joinpoint趋势分析评估发病趋势。使用STATA分析生存率。
泰国骨肉瘤的ASR为5.1/10人口年，该国每年估计有328例新诊断的骨肉瘤。骨肉瘤（52.5%）、软骨肉瘤（18%）、尤因肉瘤（11.6%）、骨巨细胞瘤（4.8%）和脊索瘤（4.7%）是最常见的恶性骨肿瘤，占所有骨肉瘤的91.5%。骨肉瘤好发于男性（1.29:1），且年龄特异性双峰发病率模式与主要组织学亚型骨肉瘤密切相关。泰国骨肉瘤患者的1年和5年生存率分别为74%和52%。骨肉瘤，尤其是骨肉瘤的生存率低于美国、欧洲和日本报告的生存率。
骨肉瘤总体生存率较低表明泰国骨肉瘤控制项目存在差距。这表明未来需要改善骨肉瘤患者的健康促进、治疗过程和化疗。
